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amelioration of markers of steatosis and liver histology in
non-cirrhotic NASH [10]. Future trials should also evaluate the
impact of experimental drugs on renal function, which is
currently reported in less than 10% of available randomized tri-
als in NASH.
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consequence of increased risk for cardiovascular morbidity and
mortality.
Efforts to minimize the comorbidity burden associated with
NAFLD may consequently decrease the risk of developing CKD.
Once CKD develops, we agree that statins and angiotensin recep-
tor blockers are helpful in select patients [5]. Unfortunately, more
effective treatments for preventing CKD progression are still
needed. Indeed, a GFR decline into stage 3 CKD (moderately
decreased GFR) is the expected consequence of normal aging
[6] and the American College of Physicians does not recommend
routine screening for moderately decreased GFR in the absence of
risk factors [5]. However, liver transplantation is an unequivocal
risk factor and monitoring for CKD is warranted.
The evolving epidemiology of end-stage liver disease presents
new challenges for the transplant community. Optimization of
long termoutcomesof liver transplant recipientsmaybe improved
with vigilant management of pre and posttransplant metabolic
syndrome and careful adjustment of the immunosuppression reg-
imen. In order to improve the medical care in this population, we
fully agree that renal function should be an investigated endpoint
for randomized trials of novel treatments for NASH.
Letters to the EditorTo the Editor:
We appreciate the comments of Musso et al. related to our
manuscript ‘‘Chronic kidney disease and associated mortality
after liver transplantation - a time-dependent analysis using
measured glomerular ﬁltration rate’’ [1]. The authors call
attention to the accumulating evidence of non-alcoholic fatty
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
as a risk factor for chronic kidney disease (CKD). As NASH cirrho-
sis is emerging as the most common cause of liver transplanta-
tion (LT) [2], the incidence of subsequent CKD may increase.
Whether the changing trends in the etiology of end-stage liver
disease requiring transplantation will impact the risk of CKD post
LT remains to be determined. The anticipated decline of hepatitis
C as a main cause of end-stage liver disease will reduce the prev-
alence of well-deﬁned HCV-associated kidney diseases, such as
cryoglobulinemia and membranoproliferative glomerulopathy
[3]. On the other hand, the increasing prevalence of obesity and
NASH is likely to offset this effect. A growing number of observa-
tions have linked NASH to the development of CKD [4]. While the
exact mechanism of this association is unclear, both share
common cardiometabolic risk factors and the ultimate clinical984 Journal of Hepatology 2015 vol. 62 j 975–989
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A scoring system for biliary atresia: Is this the right one?
To the Editor:
We read with interest the recent article by El-Guindi et al. [1].
An effective bedside diagnostic score for biliary atresia (BA) in
cholestatic infants, despite decades of clinical experience, is still
lacking, and none of the few proposed in the past achieved a
widespread application in clinical practice [2–4]. The task is
tough; the perfect score should fulﬁll two conﬂicting require-
ments. Despite the great clinical heterogeneity, a near 100%
sensitivity is mandatory because of the time-dependent surgical
treatment. On the other hand, invasive procedures, such as intra-
operative cholangiography or liver biopsy, should be avoided as
much as possible in very small children.
Starting from state-of-the-art knowledge about all previously
reported signs of BA, El-Guindi et al. formulated a new twelve-
point diagnostic score using a smart statistical approach. Subse-
quent validation on a cohort of 75 consecutive patients showed
an overall high diagnostic accuracy of 98% (sensitivity 100%,
speciﬁcity 97.6%). Because of such relevant results, we aimed to
challenge this scoring system with our historical series of
cholestatic newborns and compare results with those of our
current diagnostic protocol.
From January 2009, 64 patients were referred for neonatal
cholestasis. After initial assessment, including clinical evaluation,
ultrasound and targeted laboratory and/or radiological test to
rule out other deﬁnite diagnosis, 16 of them underwent liver
biopsy, 2 endoscopic retrograde cholangio-pancreatography,
and 18 intraoperative cholangiography. Sixteen newborns
received the diagnosis of BA and underwent Kasai procedure at
a median age of 62 days (range 34–128 days), with a median
delay of 6 days from the ﬁrst evaluation (range 1–47 days). Only
three patients were not correctly diagnosed at the end of the ﬁrst
evaluation. One patient with BA was addressed to intraoperative
cholangiography with a delay of 47 days because cholestasis was
initially ascribed to the concomitant Hypothyroidism. Con-
versely, two newborns, which later received a diagnosis of
neonatal sclerosing cholangitis and non-syndromic ductal
paucity, respectively, underwent intraoperative cholangiography.
Liver histology was available for review in 27 cases, 16 from
needle biopsy and 11 from surgical biopsy. In this series of 27
patients, we retrospectively calculated the diagnostic score of
El-Guindi et al. at the time of ﬁrst evaluation. Mean age at ﬁrst
evaluation of the 27 infants was 60.4 days (range 29–122 days),
16 children had BA and 11 another cause of neonatal cholestasis
(3 transient neonatal cholestasis, 1 cystic ﬁbrosis, 1 neonatal
sclerosing cholangitis, 1 hypothyroidism, 2 non-syndromic
ductopenia, 1 mitochondrial depletion syndrome, 1 Niemann-
Pick type C, 1 biliary acids synthesis defect).
Clinical, histological and laboratory items were extracted from
medical records. A single radiologist (MPM) with speciﬁc experi-
ence in the ﬁeld [5], unaware of ﬁnal diagnosis, reviewed all
recorded ultrasound examinations, performed after six hours of
fasting, and calculated radiological items. Among them, only gall-
bladder contractility was not possible to be evaluated from the
recorded images. This item was estimated comparing the ﬁrst
examination, performed after fasting, with other tests performed
randomly in the following days. At least one follow-up ultra-
sound was available for all patients. Prevalence of single items
of the score is showed in Table 1. Global sensitivity was 31%
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